Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Tuesday, February 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has entered into a non-exclusive patent license agreement with Caribou Biosciences. This collaboration aims to leverage Precision's ARCUS platform for developing advanced gene editing therapies. The agreement is expected to enhance the capabilities of both companies in the field of gene editing.
Price reaction · baseline $12.26 (2024-02-20T18:02:00.000Z) · hit during market hours · clean, no other DTIL news in the window
day 0 close
+5.6%
day 1
+0.8%
day 3 · peak
+8.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The agreement with Caribou Biosciences may enhance research capabilities.
  • The ARCUS platform is noted for its innovative gene editing potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 20, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is the purpose of the agreement with Caribou Biosciences?

The agreement aims to leverage Precision's ARCUS platform for advanced gene editing.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

Is the patent license agreement exclusive?

No, the agreement with Caribou Biosciences is non-exclusive.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Caribou Biosciences gene editing ARCUS platform
Last updated: Feb 20, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →